Louisiana Board of Pharmacy opens Regulatory Project 2026-01 to overhaul Controlled Dangerous Substances rules (Chapter 27), including ARCOS reports only upon request

The Louisiana Board of Pharmacy (LABP) lists an active rulemaking project (Regulatory Project 2026-01) to amend LAC Title 46, Part LIII, Chapter 27 (Controlled Dangerous Substances). The stated intent includes adopting federal controlled substance regulations by reference, consolidating Louisiana-specific provisions into §2713, repealing redundant sections, and changing distributor reporting so ARCOS-related reports would be provided to the Board only upon request (reducing routine reporting burden). Compliance teams supporting CDS registrants (manufacturers, distributors, pharmacies, etc.) should track this project because it may materially change Louisiana-specific procedural obligations and the frequency/trigger for ARCOS data submissions to the state regulator.